Ranbaxy recalls some batches of generic Lipitor in latest quality blow
Published on Mar 8, 2014 4:48 PM
MUMBAI (REUTERS) - Indian drugmaker Ranbaxy Laboratories, reeling under a flurry of regulatory rebukes due to poor quality, has recalled more than 64,000 bottles of the generic version of a cholesterol-lowering drug in the United States after dosage mix-up was detected.
Ranbaxy recalled tablets of atorvastatin calcium, the generic version of Pfizer's cholesterol fighter Lipitor, after a pharmacist found a 20-milligram tablet in a sealed bottle marked for 10-milligram tablets, the US Food and Drug Administration (FDA) said on its website.
Ranbaxy, India's biggest drugmaker by revenue and majority owned by Japan's Daiichi Sankyo, confirmed the recall of select batches of the drug, but said the company had not received any product complaints.
"Ranbaxy is proactively recalling the lots out of an abundance of caution, keeping the safety of its patients in mind and with the full knowledge of the US FDA," the company said in a statement issued to Reuters on Saturday.
To continue reading, log in if you are a subscriber
Enjoy 2 weeks of unlimited digital access to The Straits Times. Get your free access now!